An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil

NATerminatedINTERVENTIONAL
Enrollment

3,300

Participants

Timeline

Start Date

February 18, 2014

Primary Completion Date

December 20, 2018

Study Completion Date

December 20, 2018

Conditions
Dengue
Interventions
PROCEDURE

Blood sample collection

Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.

OTHER

Data collection

Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.

Trial Locations (5)

69040000

GSK Investigational Site, Manaus

Unknown

GSK Investigational Site, Salvador

GSK Investigational Site, Campinas

59025-050

GSK Investigational Site, Natal

21040-900

GSK Investigational Site, Rio de Janeiro

Sponsors
All Listed Sponsors
collaborator

Tropical Disease Foundation

OTHER

collaborator

Goncalo Moniz Research Center

OTHER

collaborator

Evandro Chagas Research Institute, Bio-Manguinhos Technology and Immunology Institute

OTHER_GOV

lead

GlaxoSmithKline

INDUSTRY